Concepedia

Yi Yu

YY

Statistics

Publications

9

Citations

409

H-Index

9

Active since

2014

Affiliations

Tango Therapeutics (United States)(Current)

First Affiliated Hospital of Nanchang University

Novartis (United States)

Dana-Farber Cancer Institute

University of California, Davis

Yi Yu is an author at Tango Therapeutics (United States) specializing in oncology, molecular oncology, and medicine.

Publications per year

2014–2025

9

Publications

9

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong et al. · Nature · 2024 · 155 citations · Full text

Medicine, Immunology, Oncology +17

Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer

Antoine Simoneau, Justin L. Engel, Madhavi Bandi et al. · Molecular Cancer Therapeutics · 2022 · 73 citations · Full text

Life Sciences, Genetics, Oncology +15

TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation

Zineb Mounir, Fallon Lin, Virginia Lin et al. · Oncogene · 2014 · 61 citations

Medicine, Oncology, Urology +15

Exendin‐4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation

He Wenjing, Yuanyuan Shao, Yi Yu et al. · The Prostate · 2020 · 28 citations

Medicine, Oncology, Pharmacology +15

Arc/Arg3.1 has an activity-regulated interaction with PICK1 that results in altered spatial dynamics

Brandee Goo, Bethany J. Sanstrum, Diana Z. Y. Holden et al. · Scientific Reports · 2018 · 27 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

1–5 of 9